Potential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: Findings from EUROASPIRE study

Atherosclerosis

Volumn 153, Issue 2, 2000, Pages 505-517

  Vanuzzo, Diego ^a   Pilotto, Lorenza ^a   Ambrosio, Giovanni B ^b   Pyörälä, Kalevi ^c   Lehto, Seppo ^c   De Bacquer, Dirk ^d   De Backer, Guy ^d   Wood, David ^e  

^a ASS 4 Medio Friuli   (Italy)

^b Venice City Hospital   (Italy)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d GHENT UNIVERSITY   (Belgium)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Cholesterol; Coronary heart disease; LDL cholesterol; Lipid lowering drugs; Secondary prevention

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SECONDARY PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANTILIPEMIC AGENTS; CORONARY DISEASE; EUROPE; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0034510288     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00596-7     Document Type: Article

References (22)

1. The value of lowering cholesterol after myocardial infarction
2. Retardation and arrest of progression or regression of coronary artery disease: A review
3. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
7. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
8. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
9. A British Cardiac Society survey of the potential for the secondary prevention of coronary heart disease: ASPIRE (Action on Secondary Prevention Through Intervention to Reduce Events). Principal results
10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
11. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Result of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
12. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Task Force of European and other Societies on Coronary Prevention
13. AHA Consensus Panel Statement. Preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel
14. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction
15. Estimation of low density lipoprotein cholesterol concentration without the use of the preparative ultracentrifuge
16. Serum cholesterol and high density lipoprotein cholesterol distributions in patients with acute myocardial infarction and in the general population of Kuopio province, Eastern Finland
17. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Göteborg, Sweden
18. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations
19. Concordance of diet with the recommended cholesterol lowering diet in patients with coronary heart disease
20. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein bypass grafts
21. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
22. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group